[A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].

Abstract

The patient was a 69-year-old woman who had undergone right standard radical mastectomy on August 8, 1991, and was treated with chemo- and hormonal therapy of ADM, UFT and TMA. Three years later she showed multiple bone metastases with elevation of CEA, and 5'-DFUR 1,200 mg/day and MPA 800 mg/day were administered. Two years later her CEA levels were decreased, 5'-DFUR was discontinued and MPA 1,200 mg/day only was continued. Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day. Then the side effect was resolved. Bone scintigraphy and MRI showed that bone metastatic lesions were reduced 6 years after 5'-DFUR and MPA therapy. It is suggested that this combination therapy may be useful for advanced recurrent breast cancer patients with multiple bone metastases.

• Authors: Toshihiro Otsuka, Yoshiyasu Terashima, Seiki Tashiro
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 29 Issue 2 Pg. 313-6 (Feb 2002) ISSN: 0385-0684 [Print] Japan
• PMID: 11865641 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Floxuridine
• Medroxyprogesterone
• doxifluridine

Topics

• Adenocarcinoma, Scirrhous (drug therapy, secondary, surgery)
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Breast Neoplasms (pathology, surgery)
• Drug Administration Schedule
• Female
• Floxuridine (administration & dosage)
• Humans
• Mastectomy, Radical
• Medroxyprogesterone (administration & dosage)
• Survivors